Clinical Trials Logo

Abortion, Habitual clinical trials

View clinical trials related to Abortion, Habitual.

Filter by:

NCT ID: NCT03766594 Completed - Clinical trials for Miscarriage, Recurrent

Sildenafil Citrate in Early Unexplained Recurrent Pregnancy Loss

Start date: January 1, 2018
Phase: Phase 1
Study type: Interventional

Recurrent unexplained spontaneous miscarriage (RSM) is defined as three consecutive pregnancy loss prior to 20 weeks from the last menstrual period. 1% to 2% of women experience RSM. Treatment of URSM is a challenging issue. The currently available lines of treatment according to simplicity of use, reliability and degree of invasiveness include corticosteroids, sildenafil citrate, aspirin, heparin and immunoglobulins (besides good antenatal care), but up to now there are no prospective randomized studies, powerful enough, to determine a significant difference between these therapeutic protocols, with any of the above mentioned pharmacological agents. Sildenafil Citrate (Viagra®), a vasodilator, is also described as an anti-inflammatory agent. While improving uterine blood flow in the proliferative phase, NO may have detrimental effects at the level of the endometrium during the implantation window. The NO- mediated release of cytokines such as tumour necrosis factor- from activated natural killer cells has been implicated as a cause of implantation failure. Based on these observations, this study attempts was made to study uterine arteries and sub-endometrial blood flow during the luteal phase in normal fertile women and in patients with Unexplained recurrent miscarriage

NCT ID: NCT03710226 Not yet recruiting - Clinical trials for Recurrent Miscarriage

Use of Platelet Indices for Prediction of Recurrent Miscarriage

Start date: December 1, 2018
Phase:
Study type: Observational

Platelet indices might be a marker for platelet activation, and thus could predict thrombosis. This might be the cause in some cases of recurrent miscarriage. This study aims to evaluate the use of platelet indices -as a simple test- to predict recurrent miscarriage.

NCT ID: NCT03703401 Recruiting - Clinical trials for Abortion, Spontaneous

The Role of Hydrosalpinx in Recurrent Miscarriage

Start date: February 28, 2018
Phase:
Study type: Observational

Miscarriage affects one in five pregnancies and little progress has been made in understanding and treating this distressing condition. C. trachomatis is the most common sexually transmitted infection in the UK. C. trachomatis infection can have serious health consequences, including fallopian tube damage. Untreated C. trachomatis infection and tubal damage have been associated with miscarriage and adverse pregnancy outcomes such as preterm birth, low birth weight and stillbirth. A cohort study is needed to establish the prevalence of tubal disease in women with recurrent miscarriages. HyCoSy will be performed to identify tubal disease and establish the magnitude of the problem in the recurrent miscarriage population. The prognosis of tubal disease on miscarriage and other obstetric outcomes, and the role of medical interventions such as tubal surgery (to treat hydrosalpinx) on reducing miscarriage and adverse obstetric outcomes will also be studied. Objectives 1. Establish the prevalence of hydrosalpinx in the recurrent miscarriage population. 2. Establish the prognosis of women diagnosed with recurrent miscarriage with concurrent hydrosalpinx. 3. Explore the role of tubal surgery for improving reproductive outcomes in women with recurrent miscarriage population and hydrosalpinx.

NCT ID: NCT03690830 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Use of Metabolomics for the Identification of Endometrial Biomarkers for IRPL and RIF After in Vitro Fertilization

ENDOMETAB
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

It is a case-control study composed of 3 groups : 2 cases groups (RIF and IRPL) already composed as part of a pre-existing research project and 1 control group including patients undergoing ART for male factor infertility. The purpose of this study is to compare the 2 case group with the control group to identify metabolomics signatures.

NCT ID: NCT03671174 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Immunosuppressant Regimens for Living Fetuses Study

Start date: September 2018
Phase: N/A
Study type: Interventional

Undifferentiated connective tissue diseases (UCTD) are known to increase the risk of pregnancy morbidities, including recurrent pregnancy loss. However, there is no consensus or guideline about the treatment for recurrent pregnancy loss in UCTD patients. Therefore, based on the tendency to thrombosis formation and placental inflammation in the pathogenesis of UCTD, this trial proposes to evaluate the effect of hydroxychloroquine with or without prednisone combined with anticoagulation on pregnancy outcomes in recurrent pregnancy loss patients with UCTD.

NCT ID: NCT03577314 Recruiting - Oral Health Clinical Trials

Is There an Interaction Between Recurrent Miscarriage and Dental Health

Start date: April 15, 2018
Phase:
Study type: Observational

Oral infections can trigger the production of pro-inflammatory mediators that may be risk factors for miscarriage. The investigators investigated whether oral health care patterns that may promote or alleviate oral inflammation were associated with the history of miscarriage in Turkish women.

NCT ID: NCT03475160 Completed - Recurrent Abortion Clinical Trials

Sildenafil Citrate and Recurrent Abortion

Start date: December 1, 2015
Phase: N/A
Study type: Interventional

Two groups of unexplained recurrent spontaneous abortion, each included 65 participants. scheduled randomly into; the study group received Sildenafil Citrate and Placebo group. The intervention started from day 21-23 of the cycle preceding spontaneous pregnancy and continued till the 12th-week of gestation. The primary outcome measure was the difference in the live birth between both groups. Secondary outcome measures were the differences between both groups regard pulsatility index (PI) and resistance index (RI), a number of take-home babies, the reported side-effects of treatment and the pregnancy-related complications.

NCT ID: NCT03401918 Recruiting - Clinical trials for Unexplained Infertility

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

Start date: September 6, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if patients with recurrent pregnancy loss or unexplained infertility have an altered uterine gene expression or uterine microbiome (micro-organism composition) during the window of embryo implantation. Furthermore we would like to assess for women with an abnormal uterine gene expression whether vaginal progesterone medication improves or alters gene expression and for women with an abnormal microbiome whether antibiotic treatment followed by probiotic treatment normalizes the microbiome.

NCT ID: NCT03384082 Not yet recruiting - Arcuate Uterus Clinical Trials

Reproductive Prognosis After Therapies for Uterus Arcuatus Following Recurrent Miscarriage Women

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

82 cases of recurrent miscarriage women with a diagnosis of arcuate uterus, confirmed by three-dimensional intra-vaginal sonography (3D-TVS) and hysteroscopy, will be recruited. The subjects will be randomly divided into two groups, the experimental group will be given hysteroscopic treatment, the control group will receive no treatment. The pregnancy rates (>12 weeks) of the two groups will befollowed and compared.

NCT ID: NCT03336463 Completed - Clinical trials for Miscarriage, Recurrent

Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score

TiC-RPL
Start date: February 2015
Phase: N/A
Study type: Observational

Recurrent pregnancy loss (RPL) is a clinical problem affecting 1-5% of couples of reproductive age. The contribution of thrombophilia to RPL is disputed. This controversy is partly due to low sensitivity of the genetic variants currently used to evaluate hereditary thrombophilia: the Leiden mutation (identified as rs6025) in the coagulation factor 5 (F5L) gene and mutation G20210A (identified as rs1799963) in the prothrombin (PT) gene. Our objective was to determine whether a wider algorithm that includes clinic and genetic variants associated with thrombophilia could be more useful in the prediction for RPL than FVL and PT alone.